醫療藥物開發委託機構市場 - 2016年止展望 是由出版商Business Insights在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 154 價格從美金3835起跳。
2011年因產生了明顯經濟問題 ，使醫療產業受到前所未有之財務表現壓力，小型企業在資金調度不足、垂直整合、風險分擔、整體研發費用增加、生技發展、適應臨床實驗、ePRO等技術上，開始多方使用開發委託機構（CRO）。
本報告為，探討美國、東西歐、中國、印度、中南美之醫療藥物開發委託機構市場，並匯整主要企業競爭力概要、2016年止市場趨勢預測等最新資訊，以下列摘要形式闡述。
實施概要
- 改變之研發環境
- 委託開發持續成長
- 先進地區持續之需求
- 新興地區強勢之成長
- 全球主要開發委託機構之最佳使用方式
- 開發委託業之未來
關於作者
改變之研發環境
- 摘要
- 簡介
- 醫療藥物許可過程
- 原有之新興醫療藥物市場壓力及壓力增長
- 銷售佳產品之專利失效及非專利藥物化
- 生物製劑
- 研發費用增加
- 研發人員及預算減少
- 無法隨性確保臨床研究人員
- 新的法規及法令
- 藥劑許可案件減少
- 資本市場規範
- 藥劑開發之當務之急
- 結論
委託開發持續成長
- 摘要
- 醫療藥物開發委託機構（CRO：Contract research organizations）
- 開發委託機構使用率 2010-2016
- 全球開發委託機構之藥劑階段別預測
- 全球開發委託機構之地區別業績預測
- 開發委託機構使用增加之要因
- 垂直整合
- 風險分擔
- 研發費用增加
- 生技增加
- 適應臨床實驗
- 先進技術
- 開發委託機構之阻力
- 強化醫療藥物產業體質
- 加強開發委託機構體質及競爭
- 減少研發費用
- 開發委託機構人員不足
先進地區持續之需求
- 摘要
- 簡介
- 美國開發委託機構市場
- 歐洲開發委託機構市場
- 結論
新興地區強勢之成長
- 摘要
- 簡介
- 東歐開發委託機構市場
- 中國開發委託機構市場
- 印度開發委託機構市場
- 亞洲（中國、印度外）開發委託機構市場
- 中南美開發委託機構市場
全球主要開發委託機構之最佳使用方式
開發委託業之未來
附錄
Description
INTRODUCTION
This report examines CRO markets in the US, Eastern Europe, Western Europe, China, India, Other Asia, and Latin America. Leading players are profiled and compared according to capability. The report also maps out the the future of the industry through to 2016.
FEATURES AND BENEFITS
- Forecast the market size for contract research in the US, Eastern Europe, Western Europe, China, India, Other Asia, and Latin America.
- Discover the opportunities presented by emerging CRO markets and optimize your research sourcing strategies.
- Understand how CRO utilization is evolving, and what the future of the industry is.
- Assess the growth potential of the industry and understand how leading players are taking advantage of the opportunities in this market.
- Compare and contrast capabilities of leading CROs in each region and identify potential partners or rivals.
HIGHLIGHTS
New economic challenges coming to light in 2011 will further pressure the industry, making drug maker financial performance even more important and tightening access to capital for smaller players.
A variety of factors are fueling strong and continued increases in CRO usage including vertical integration, risk sharing programs, overall growth of R&D spending, biotech expansion, adaptive trials, and technology such as ePRO.
In 2012 and 2013, economic and industry pressures will have the net effect of reducing overall drug development activity, particularly R&D conducted in-house. Although contract services will also be affected, they will continue to be considered more attractive, with a higher cost-benefit ratio than in-house drug development.
YOUR KEY QUESTIONS ANSWERED
- What factors are underpinning the growth of the CRO market?
- Why is M&A activity of CROs high and why will this continue?
- How is demand for different types of CRO services changing?
- Which are the leading CROs in each region and why?
- What regions will experience the greatest growth of CRO activity and how can drug developers optimize their work with CROs in these areas?
Table of Contents
Executive Summary
- The shifting R&D landscape
- The continued growth of contract R&D
- Continued demand in the established regions
- Strong growth in the emerging regions
- Leading global CROs and best practices
- The future of contract research
About the author
The shifting R&D landscape
- Summary
- Introduction
- The drug approval process
US
- Rising pressures on established and emerging drug makers
- Blockbuster patent expirations and genericization
- Biosimilars
- Escalating R&D costs
- Reduced R&D staff and budgets
- Delays in clinical study recruitment
- New regulations and legislation
- Heightened regulatory scrutiny
- Decreasing drug approvals
- Constrained capital markets
- Drug development imperatives
- Targeting large markets
- Decreasing time to launch
- Conclusion
The continued growth of contract R&D
- Summary
- Contract research organizations
- The role of CROs
- Services offered by CROs
- CRO usage, 2010-2016
- Global CRO forecasts by phase of drug
- Global CRO forecasts by world region
- Drivers of rising CRO usage
- Vertical integration
- Risk sharing programs
- Growth of R&D spending
- Biotechnology expansion
- Adaptive trials
- Technology
- Restraints inhibiting greater CRO usage
- Pharma industry consolidation
- CRO consolidation and competition
- R&D budget reductions
- CRO personnel shortages
- Conclusion
Continued demand in the established regions
- Summary
- Introduction
- The US CRO market
- Overview
- US CRO usage by phase of drug, 2010-16
- The Western European CRO market
- Overview
- Western European CRO usage by phase of drug, 2010 - 2016
- Conclusion
Strong growth in the emerging regions
- Summary
- Introduction
- The Eastern European CRO market
- Overview
- Eastern European CRO usage by phase of drug, 2010-16
- The Chinese CRO market
- Overview
- Chinese CRO usage by phase of drug, 2010-2016
- The Indian CRO market
- Overview
- Indian CRO usage by phase of drug, 2010-16
- The Asian CRO market, exclusive of China and India
- Overview
- Other Asian CRO usage by phase of drug, 2010 - 2016
- The Latin American CRO market
- Overview
- Latin American CRO usage by phase of drug, 2010 - 2016
Leading global CROs and best practices
- Summary
- Introduction
- Leading players
PPD
- Charles River Laboratories
- PAREXEL International
ICON
- Ricerca
- Kendle/INC Research
- PRA International
- WuXi AppTec
- PharmaNet/inVentiv
- Case studies
- Employee retention: Quintiles
- Service expansion: Covance
- Service innovation: PAREXEL
- Global expansion: ICON plc
- Vertical integration: WuXi AppTec
- Conclusion
The future of contract research
- Summary
- Introduction
- The drug development landscape in the US and EU
- Near term: 2012 - 2013
- Long term: 2014 - 2016
- R&D outsourcing trends
- Near term: 2012 - 2013
- Long term: 2014 - 2016
- Conclusion
Appendix
- Scope
- Methodology
- Primary research
- Secondary research
- Sources used
- Glossary/Abbreviations
